Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Faculty Members have conducted research related to the A Randomized, Two-Armed, Double-Blind, Single-Dose, Cross-Over, Bioequivalence Clinical Trial to Compare Pharmacokinetic Parameters and Safety of Recombinant Human Factor Viii With Fc Fusion Produced by Aryogen Pharmed Company Versus Elocta® (Reference Product) in Previously Treated Patients With Severe Haemophilia A
Majid Ghanavat
Majid Ghanavat

Assistant Professor of Pediatric Hematology and Oncology

Department of Pediatrics, School of Medicine

Isfahan University of Medical Sciences

All Documents
1. A Randomized, Two-Armed, Double-Blind, Single-Dose, Cross-Over, Bioequivalence Clinical Trial to Compare Pharmacokinetic Parameters and Safety of Recombinant Human Factor Viii With Fc Fusion Produced by Aryogen Pharmed Company Versus Elocta® (Reference Product) in Previously Treated Patients With Severe Haemophilia A, Annals of Hematology (2025)
2. A Randomized, Two-Armed, Double-Blind, Single-Dose, Cross-Over, Bioequivalence Clinical Trial to Compare Pharmacokinetic Parameters and Safety of Recombinant Human Factor Viii With Fc Fusion Produced by Aryogen Pharmed Company Versus Elocta® (Reference Product) in Previously Treated Patients With Severe Haemophilia A, Annals of Hematology (2025)
3. Pineal Germinoma Presented With Paralysis of Upward Gaze and Diabetes Insipidus, Acta Endocrinologica (2023)
4. Bloodstream Infections in Febrile Hematologic Oncology Patients in a Referral Hospital in Ahvaz, Iran: A Descriptive Cross-Sectional Study, Iranian Journal of Medical Sciences (2022)
5. Digging Deeper Through Glucose Metabolism and Its Regulators in Cancer and Metastasis, Life Sciences (2021)
6. The Effect of Inflammatory Factors and Their Inhibitors on the Hematopoietic Stem Cells Fate, Cell Biology International (2021)
7. Altered Expression and Functional Role of Ion Channels in Leukemia: Bench to Bedside, Clinical and Translational Oncology (2020)
8. Cardiomyopathy in Thalassemia: Quick Review From Cellular Aspects to Diagnosis and Current Treatments, Lab Medicine (2020)
9. Cd Markers Polymorphisms As Prognostic Biomarkers in Hematological Malignancies, Oncology Reviews (2020)
10. Essential Thrombocythemia: A Hemostatic View of Thrombogenic Risk Factors and Prognosis, Molecular Biology Reports (2020)
11. The Relation Between Different Aspects of Quality of Life With Coping Style in Adolescents With Thalassemia in Comparison to a Healthy Group, International Journal of Hematology-Oncology and Stem Cell Research (2020)
12. Clonal Hematopoiesis: Genes and Underlying Mechanisms in Cardiovascular Disease Development, Journal of Cellular Physiology (2019)
13. H19: A Regulatory Biomarker With Prognostic Value in Leukemias, Eurasian Journal of Medicine and Oncology (2019)
14. Prognostic Significance of Aberrant Cd5 Expression in B-Cell Leukemia, Oncology Reviews (2019)
15. Role of Bone Marrow Adipocytes in Leukemia and Chemotherapy Challenges, Cellular and Molecular Life Sciences (2019)
16. Singe Nucleotide Polymorphisms in Osteosarcoma: Pathogenic Effect and Prognostic Significance, Experimental and Molecular Pathology (2019)
17. The Effect of Combination Iron Chelating Agents on Reducing the Severity Grading of Heart and Liver Iron Overload in Β-Thalassemia Patients, Iranian Journal of Pediatric Hematology and Oncology (2019)
18. Thrombocytopenia in Solid Tumors: Prognostic Significance, Oncology Reviews (2019)